drugset
drugset / Trial / NCT00225173

Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease

NCT00225173 ↗

Phase 2 Terminated 45 enrolled Stanford University National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

Patients with 3 or more adverse prognostic factors have a higher relapse rate. Significant anti-tumor activity in Hodgkin's lymphoma has been reported with two new drugs:gemcitabine and vinorelbine. The introduction of these new agents with their different mechanisms of action into the Stanford V regimen may increase effectiveness while maintaining a favorable toxicity profile with respect to fertility and a low risk of secondary leukemia. On this basis, we propose a new regimen, Stanford VI, for patients with bulky and advanced HD with 3 or more risk factors.

Timeline

Start
2001-10
Primary completion
2005-09
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bleomycin Unknown 5 iu/kg Intravenous
Subject Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 25 mg/m2 Intravenous
Subject Etoposide Small molecule 60 unknown Intravenous
Subject Gemcitabine Small molecule 1250 mg/m2 Intravenous
Subject Prednisone Other / unclassified 40 mg/m2 Oral
Subject Vinblastine Small molecule 6 mg/m2 Intravenous
Subject Vincristine Small molecule 1.4 mg/m2 Intravenous
Subject Vinorelbine Small molecule 25 mg/m2 Intravenous

Indications

Hodgkins lymphoma